Document is current
Any future updates will be listed below
-
Authors
Tan, Carlyn Rose https://orcid.org/0000-0001-7922-2594
Estrada-Merly, Noel
Landau, Heather https://orcid.org/0000-0002-3152-1189
Lekakis, Lazaros
Banerjee, Rahul
Mian, Hira https://orcid.org/0000-0003-1584-1067
Usmani, Saad Z.
Hanbali, Amr
Lazarus, Hillard M. https://orcid.org/0000-0002-1159-5607
Kyle, Robert A.
Dholaria, Bhagirathbhai https://orcid.org/0000-0003-2371-3655
Bal, Susan
Strouse, Christopher https://orcid.org/0000-0003-4964-167X
Murthy, Hemant S.
Wirk, Baldeep https://orcid.org/0000-0002-2804-2531
Nishihori, Taiga https://orcid.org/0000-0002-2621-7924
Kumar, Shaji https://orcid.org/0000-0001-5392-9284
Shah, Nina
Qazilbash, Muzaffar https://orcid.org/0000-0003-2876-2886
D’Souza, Anita https://orcid.org/0000-0002-1092-5643
- License Information
-
More Information
Article History
Received: 26 July 2021
Revised: 28 October 2021
Accepted: 5 November 2021
First Online: 20 November 2021
Competing interests
: Dr. Dholaria reports institutional research support from Takeda, Janssen, Angiocrine, Pfizer, Poseida. Údvisory board for Jazz. Dr. Banerjee reports grants from Pack Health, personal fees from SparkCures, outside the submitted work. Dr. Mian reports grants from Janssen and consulting fees from Janssen, BMS, Takeda, Sanofi, Amgen, GSK. Personal fees from Amgen, Sanofi, BMS/Celgene, Janssen. Board of directors for Myeloma Canada. Dr. Tan reports other financial interests—spouse employed by Janssen R&D. Dr. Usmani reports grants and personal fees from Amgen, personal fees from Abbvie, grants from BMS, grants and personal fees from Celgene, personal fees from MundiPharma, grants from Pharmacyclics, grants and personal fees from Sanofi, grants and personal fees from Seattle Genetics, grants and personal fees from Janssen, grants and personal fees from Takeda, grants and personal fees from SkylineDX, grants and personal fees from Merck, grants and personal fees from GSK, outside the submitted work. Dr. Murthy reports board participation for CRISPR Therapeutics. Dr. Qazilbash reports data safety board participation for Autolus and the advisory board for Oncopeptides. Dr. Dholaria reports institutional research funds from Janssen, Poseida, Angiocrine, Takeda. Personal advisory funds from Jazz. Dr. Kumar reports institutional research support for clinical trials from Abbvie, Celgene, Janssen, Takeda, Adaptive, KITE, Medimmune/Astra Zeneca, Merck, Novartis, Roche, and Sanofi. Advisory board participation paid to the institution from Abbvie, Celgene, Janssen, Takeda, Adaptive, KITE, and Medimmune/Astra Zeneca and Oncopeptides independent review committee. Dr. Nishihori reports research support outside of the submitted work paid to the institution from Norvartis and Karyopharm. Dr. Strouse reports consulting fees from Bristol Meyer Squibb. Dr. Landau reports grant support from Takeda Pharmaceuticals, payment or honoraria from Genzyme corporation. Participation on board for Janssen, Genzyme, Celgene. Dr. D’Souza reports grant support from Takeda, TeneoBio, Sanofi, Caelum and Prothena, consulting fees from Janssen, and advisory board participation fees from Imbrium, Pfizer and BMS.
